金吾财讯| 香港联交所上市公司今海医疗科技股份有限公司（股份代号：2225）于2025年3月21日发布盈利警告称，预计截至2024年12月31日止年度（2024财年）税后亏损约1810万新加坡元，较2023财年的410万新加坡元亏损显著扩大。尽管集团整体业务呈现平稳发展态势，但行政费用的大幅增加成为亏损主因。公告显示，2024财年公司实现收益5020万新加坡元，同比增长约10.1%；毛利为1140万新加坡元，同比下降约5%。尽管收入规模扩大，但净亏损同比增加341.5%，主要由于向员工授予购股权产生的1330万新加坡元以股权结算的股份支付费用。该笔开支为一次性非现金项目，直接拉低了净利润表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.